Literature DB >> 19553071

Major complications associated with femoral nerve catheters for knee arthroplasty: a word of caution.

Robert J Feibel1, Geoffrey F Dervin, Paul R Kim, Paul E Beaulé.   

Abstract

One thousand one hundred ninety patients underwent knee arthroplasty between January 2004 and July 1, 2007, and received an indwelling continuous infusion femoral catheter for postoperative ropivicaine pump infusion. Catheters were placed using electrical stimulation guidance. For the initial 469 patients (group 1), the continuous infusion ran for 2 to 3 days. In 721 patients, the infusion was discontinued 12 hours after surgery. There were 9 femoral nerve palsies (2 in group 1, 7 in group 2) and 8 major falls (0.7%). The overall complication rate was 1.5%, and the risk of permanent nerve injury was 0.2%. Patients should be made aware of these complications as part of the usual informed consent process before using this technique for postoperative pain control after knee arthroplasty. We did not observe fewer falls when the continuous infusion was stopped 12 hours after surgery.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19553071     DOI: 10.1016/j.arth.2009.04.008

Source DB:  PubMed          Journal:  J Arthroplasty        ISSN: 0883-5403            Impact factor:   4.757


  38 in total

Review 1.  Regional analgesia for improvement of long-term functional outcome after elective large joint replacement.

Authors:  Arthur Atchabahian; Gary Schwartz; Charles B Hall; Claudette M Lajam; Michael H Andreae
Journal:  Cochrane Database Syst Rev       Date:  2015-08-13

Review 2.  Analgesic efficacy and quadriceps strength of adductor canal block versus femoral nerve block following total knee arthroplasty.

Authors:  Dong Li; Guo-Guang Ma
Journal:  Knee Surg Sports Traumatol Arthrosc       Date:  2015-11-26       Impact factor: 4.342

Review 3.  Pain after knee arthroplasty: an unresolved issue.

Authors:  Irina Grosu; Patricia Lavand'homme; Emmanuel Thienpont
Journal:  Knee Surg Sports Traumatol Arthrosc       Date:  2013-11-08       Impact factor: 4.342

4.  Clinical spectrum of neuropathy after primary total knee arthroplasty: A series of 54 cases.

Authors:  Scott J A Speelziek; Nathan P Staff; Rebecca L Johnson; Rafael J Sierra; Ruple S Laughlin
Journal:  Muscle Nerve       Date:  2019-04-04       Impact factor: 3.217

Review 5.  Falls and major orthopaedic surgery with peripheral nerve blockade: a systematic review and meta-analysis.

Authors:  R L Johnson; S L Kopp; J R Hebl; P J Erwin; C B Mantilla
Journal:  Br J Anaesth       Date:  2013-02-24       Impact factor: 9.166

Review 6.  Potential superiority of periarticular injection in analgesic effect and early mobilization ability over femoral nerve block following total knee arthroplasty.

Authors:  Huichao Fu; Jiaxing Wang; Wen Zhang; Tao Cheng; Xianlong Zhang
Journal:  Knee Surg Sports Traumatol Arthrosc       Date:  2015-01-28       Impact factor: 4.342

7.  Continuous femoral nerve block using 0.125% bupivacaine does not prevent early ambulation after total knee arthroplasty.

Authors:  Michael J Beebe; Rachel Allen; Mike B Anderson; Jeffrey D Swenson; Christopher L Peters
Journal:  Clin Orthop Relat Res       Date:  2014-05       Impact factor: 4.176

8.  Intra-articular Analgesia and Discharge to Home Enhance Recovery Following Total Knee Replacement.

Authors:  Shivi Duggal; Susan Flics; Charles N Cornell
Journal:  HSS J       Date:  2014-11-12

9.  Adverse events in total knee arthroplasty: Results of a physician independent survey in 260 patients.

Authors:  Stephan Kirschner; Jörg Lützner; Klaus-Peter Günther; Maria Eberlein-Gonska; Frank Krummenauer
Journal:  Patient Saf Surg       Date:  2010-08-11

10.  Continuous adductor canal blocks are superior to continuous femoral nerve blocks in promoting early ambulation after TKA.

Authors:  Seshadri C Mudumbai; T Edward Kim; Steven K Howard; J Justin Workman; Nicholas Giori; Steven Woolson; Toni Ganaway; Robert King; Edward R Mariano
Journal:  Clin Orthop Relat Res       Date:  2014-05       Impact factor: 4.176

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.